Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 8Neoplasms 7Colorectal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 5Breast Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Glioma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Hematologic Neoplasms 3

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × Leukemia, Myelomonocytic, Juvenile × Clear all
NCT02447666 2019-07-11

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Celgene

Phase 2 Completed
28 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡